Organization Profile

You just read:

Aeterna Zentaris Presents Preclinical Data for Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, at AACR Meeting

News provided by

Aeterna Zentaris Inc.

Apr 03, 2012, 07:30 ET